hrp0082p2-d2-380 | Fat Metabolism & Obesity (1) | ESPE2014

A New Case of Proopiomelanocortin Deficiency

Fuentes-Bolanos Noemi Auxiliadora , Madueno Francisco Jose Tinahones , Gonzalez Luis Castano , Gea Isabel Leiva , Ollero Maria Jose Martinez-Aedo , Lopez-Siguero Juan Pedro

Introduction: The proopiomelanocortin is a polypeptide of many biologically active peptides involved in many key functions which have not yet been clarified. The mutation in the gene encoding this polypeptide is associated with a clinical trials characterized by early-onset obesity, terciary adrenal insufficiency, and alteration of pigmentation. Eight cases with known genetic mutation have been published.Case report: Newborn male 27 days old from North A...

hrp0082p2-d2-424 | Growth Hormone (1) | ESPE2014

What Dose of hGH is Adequate as a Substitution Therapy in GH Deficient Children?

Voutetakis Antonis , Magiakou Maria-Alexandra , Dacou-Voutetakis Catherine , Chrousos George , Kanaka-Gantenbein Christina

Background: After 50 years of hGH use for GH deficient (GHD) children the definition of the adequate hGH substitution dose and response remain uncertain.Objective and hypotheses: We hypothesized that subjects with GHD caused by congenital pituitary defects constitute an ideal model for defining substitution dose of hGH. Consequently, an appropriate study group was formed and pertinent long-term data were retrospectively analyzed.Me...

hrp0082p2-d3-443 | Growth Hormone (2) | ESPE2014

The Effect of Two Different GH Dosages on Final Height and Bone Geometry

Lupi Fiorenzo , Bozzola Mauro , Buzi Fabio , Longhi Silvia , Mascolo Amelia , Pilotta Alba , Porto Rossella , Ruffinazzi Giulia , Zattoni Valentina , Radetti Giorgio

Background: GH has a strong positive influence on bone stimulating both bone elongation and increase in size by enhancing the accrual of trabecular and cortical bone up to the attainment of peak bone mass in young adult.Aim of the study: We compared the effect of two different GH dosages on statural growth and bone geometry in two groups of GH-deficient children at final height. Data has been collected retrospectively from 1994 to 2013.<p class="abst...

hrp0082p2-d2-461 | Growth (1) | ESPE2014

Anophthalmia, Abnormal Pituitary Development, and Suboptimal Response to GH Therapy in Two Children With Microdeletions of 14q22q23

Dusatkova Petra , Slamova Zuzana , Sumnik Zdenek , Simandlova Martina , Zemankova Elsa , Sedlacek Zdenek , Lebl Jan

Background: Microdeletions of 14q22q23 have been associated with eye abnormalities. Other symptoms in deletion carriers are less well recognized.Objective and hypotheses: We focused on growth characteristics and response to GH treatment in two unrelated children with 14q22q23 deletions.Method: Array comparative genomic hybridisation (aCGH).Results: Both patients displayed bilateral anophthalmia. Their brain M...

hrp0082p2-d3-475 | Hypoglycaemia | ESPE2014

Long-Term Follow Up of Children with Congenital Hyperinsulinism on Octreotide Therapy

Demirbilek Huseyin , Shah Pratik , Arya Ved Bhushan , Hussain Khalid

Background: Octreotide, a long-acting somatostatin analogue, is commonly used in diazoxide unresponsive congenital hyperinsulinism (CHI) patients as a second line medication. However, there are no large studies evaluating long-term follow-up CHI patients on octreotide therapy.Objective and hypotheses: To evaluate the dose range, side effects and long-term follow-up in CHI patients on daily octreotide injections.Method: Twenty-eight...

hrp0082p2-d3-481 | Hypoglycaemia | ESPE2014

Presentation, Clinical and Genetic Outcomes in a Series of Infants With Congenital Hyperinsulinism

Carroll Aoife , Gibney Brian , McDonnell Ciara , Moloney Sinead , Monavari Ardeshir , Murphy Nuala

Background: Congenital hyperinsulinism (CHI) is a rare condition but a significant cause of recurrent hypoglycaemia in infancy and childhood. Prompt recognition and appropriate management is important to avoid long-term neurological sequelae.Objective and hypotheses: To describe the presentation, clinical and genetic outcomes in a series of infants with CHI.Method: Retrospective case series of 35 patients diagnosed with CHI between...

hrp0082p2-d1-538 | Puberty and Neuroendocrinology | ESPE2014

Acute Exposure of Endocrine Disruptor does not Induce Oxidative Stress in the Rat’s Brain

Kumar Neeraj , Sharma Varsha

Background: The ever increasing uses of electronic gadgets are becoming a widespread source of Bisphenol-A accumulation. As studies have been reported that low level BPA accumulation may produce neurological effects but still limited studies have re-examined for its adverse effects in terms of acute exposure from electronic devices.Objective and hypotheses: To investigate the effects of BPA on oxidative damage in terms of activity level of antioxidant en...

hrp0082p2-d1-539 | Puberty and Neuroendocrinology | ESPE2014

Dramatic Rise in the Prevalence of Precocious Puberty in Girls Over the Past 20 Years in the South of France

Gaspari Laura , Morcrette Emilie , Jeandel Claire , Vale Fabienne Dalla , Paris Francoise , Sultan Charles

Background: Epidemiological evidence in Europe indicates the increasing prevalence of premature puberty, especially in girls. This may be attributed to in utero and early-life exposure to environmental estrogen-like compounds present in pesticides, plastics (bisphenol A, phtalates …) and beauty products.Objective and hypotheses: The aim of this study was to assess the prevalence of premature thelarche (PT) and central precocious puberty (C...

hrp0082p2-d3-610 | Turner Syndrome | ESPE2014

Therapeutic Effects of GH Combined with Low-Dose Stanozolol on Growth Velocity and Final Height of Girls with Turner Syndrome

Chen Hong-Shan , Du Min-Lian , Li Yan-Hong , Xiong Hui , Ma Hua-Mei , Chen Qiu-Li

Objective: This study aimed to investigate the therapeutic effects of recombinant human GH (rhGH) combined with low-dose stanozolol on the growth and final adult height (FAH) of girls with Turner syndrome (TS).Method: A total of 47 girls with TS were treated with rhGH (47.6–52.4 μg/kg per day) and low-dose stanozolol (20–35 μg/kg per day), starting at a mean age of 12.57±1.96 year. The control group consisted of 26 girls with TS,...

hrp0082p3-d1-625 | Adrenals &amp; HP Axis | ESPE2014

A Pediatric Case of Cushing’s Disease Presenting with Diabetic Ketoacidosis

Catli Gonul , Tanrisever Ozgur , Sule Can P , Nuri Dundar Bumin

Background: Cushing syndrome is very rare in childhood and adolescence and often occurs with iatrogenic causes. The major cause of endogenous Cushing syndrome is Cushing’s disease, which results due to excessive ACTH secretion from pituitary cells (corticotroph adenoma).Objective and hypothesis: Cushing syndrome cases, which presented with diabetic ketoacidosis (DKA) in adulthood have been rarely reported. However, to our knowledge, there is no repo...